Brought to you by 
Fovea closes €20.5mm Series A round
04 Jan 2006
Executive Summary
Named after a part of the eye responsible for central, sharper vision, start-up biotech Fovea Pharmaceuticals SA (developing treatments for retinal diseases) received €20.5mm ($25mm) in Series A investments from Sofinnova Partners, Abingworth Management, Wellcome Trust, GIMV, and Credit Agricole Private Equity. Sofinnova, which seeded the company in May 2005, led the round.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Fovea closes €20.5mm Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice